





- Analyze data and outcomes to design effective trials
- Assess clinical strategies & R&D trends
- Benchmark your asset against emerging data
- Quickly extract data across trial variables including design, tumor indication, target/MoAs, outcomes, competitors, SoC, technology platforms

1750+
Active Oncology
Clinical Trials

1100+
Heme
Malignancy Clinical
Trials

650+
Solid
Tumors Clinical Trials

250+ Fields Analyzed 240+
Indications including rare cancers

250+

Corporate Entities

Gain insights on construct designs, engineered platforms, potential biomarkers, emerging targets & treatments, efficacy & safety outcomes

Compare

**Explore** 

Benchmark


Granular

Comprehensive

Dynamic

Most Comprehensive "Oncology Cell & Gene Therapy" Clinical Trial Analytics

To talk to our experts and get a demo of the Cell & Gene Therapy Intelligence Platform, please connect with us here.



FutureBridge's tumor specific reports provide comprehensive view and foundational data on solid tumors and hematological malignancies. These reports include:

- Disease overview
- Current and emerging segments, treatment practices, standards of care, benchmarks
- Epidemiology
- Competitive landscape of key emerging assets in pipeline, and their estimated launch timelines
- Residual unmet needs
- Target Product Profile to identify opportunity for differentiation

### **Unique Features**

- Customizable reports as per client's need
- Real-time updates by tracking major oncology conferences, trial databases and read-outs, competitors' websites, Company press releases, and milestone data
- Detailed and in-depth insights into the future oncology landscape and trends
- Covers geographical nuances of current and emerging landscape

**FutureBridge** 

# Tumor Landscape Report Series



Tumor Specific Concise Reports on Current & Emerging Treatments, Trends & Future Directions

		Tumor/Indication Coverage	
Solid Tumors	Lung Cancer  Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer (SCLC) Mesothelioma  Breast Cancer Triple Negative Breast Cancer (TNBC) HER2+ Breast Cancer HR+ Breast Cancer Breast Cancer Frostate Cancer Prostate Cancer (PrCa) Renal Cancer (RCC) Testicular Cancer Bladder Cancer	Gastro-intestinal Cancer  Colorectal Cancer (CRC) Gastric Cancer Esophageal Cancer Liver Cancer (HCC) Pancreatic Ca (PaCa) Anal cancer Rectal cancer Biliary Cancer Gynaecological Cancer Endometrial Cancer Cervical Cancer Ovarian Cancer (OvCa)	Head & Neck Cancer (SCCHN)  Thyroid Cancer  Melanoma  Uveal melanoma  Non melanoma skin cancers  Cutaneous squamous cell carcinoma (CSCC)  Basal cell carcinoma (BCC)  Merkel Cell Carcinoma (MCC)  Soft Tissue Sarcoma (STS)  Neuroendocrine Tumors (NET)
	B-Cell Lymphoma & Leukemia Diffuse large B-cell lymphoma (DLBCL) Edlicular Lymphoma (FL)	Plasma Cell Disorders • Multiple Myeloma (MM)	Mature T-Cell Lymphoma  • Peripheral T cell Lymphoma (PTCL) • Cutaneous T cell Lymphoma (CTCL)

## Hematological Malignancies

- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Acute Myeloid Leukemia (AML)
- Acute Lymphocytic Leukemia (ALL)
- Marginal Zone Lymphoma (MZL)
- Chronic Lymphocytic Leukemia (CLL)/ Small Small Lymphocytic Lymphoma (SLL)

#### **B-Cell Lymphoma**

- Hodgkin Lymphomas (HL)
- Waldenstrom Macroglobulinemia (WM)

### Myelodysplastic syndromes (MDS)

Cutaneous T cell Lymphoma (CTCL)